MERRIMACK PHARMACEUTICALS INC

1. Issuer enters the archive

   Jul 8, 2011

   MERRIMACK PHARMACEUTICALS INC is represented as an issuer-level entity with 1 linked public-market ticker lifecycle.

2. Delisting event

   May 10, 2024

   SEC 25 delisting filing recorded for baseline coverage.

   Source

3. C1274792 stopped trading

   May 10, 2024

   C1274792 is linked to MERRIMACK PHARMACEUTICALS INC and ended with final status "merged".

   Source

Source-Backed Claims

• Merrimack Pharmaceuticals, Inc. entered into a definitive agreement with Ipsen S.A. for an asset sale transaction valued at up to $1.025 billion, plus up to $33 million in net milestone payments, on January 8, 2017.DEFM14A
• The asset sale included the sale of Merrimack's commercial product ONIVYDE, including U.S. commercialization rights, and their generic version of doxorubicin hydrochloride liposome injection, MM-436.DEFM14A
• Merrimack's Board of Directors recommended that stockholders vote FOR the proposed asset sale at the Special Meeting scheduled for March 30, 2017.DEFM14A
• Merrimack will receive $575 million in cash at closing and may receive up to $450 million in additional milestone payments from Ipsen upon regulatory approvals.DEFM14A
• Following the asset sale, Merrimack expected to return at least $200 million to stockholders through a special cash dividend estimated at $1.54 per share.DEFM14A
• Merrimack's Special Meeting of Stockholders was scheduled to take place on March 30, 2017, at 10:00 a.m. at the offices of Skadden, Arps, Slate, Meagher & Flom LLP in Boston, MA.DEFM14A
• As part of the asset sale, Merrimack planned to utilize approximately $195 million in proceeds to reduce long-term debt obligations.DEFM14A
• On January 6, 2017, Merrill Lynch and Credit Suisse each rendered a financial opinion on the fairness of the consideration to be received in the asset sale.DEFM14A